CareDx, Inc.
69.21USD
+0.0500 (+0.07%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on CDNA.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 321.8M | 280.3M | 333.8M | 379.8M | 495.1M | 526.0M |
| Q1 | 79.4M | 77.3M | 72.0M | 84.7M | 117.7M | — |
| Q2 | 80.6M | 70.3M | 92.3M | 86.7M | 131.9M | — |
| Q3 | 79.4M | 67.2M | 82.9M | 100.1M | 122.0M | — |
| Q4 | 82.4M* | 65.6M* | 86.6M* | 108.4M* | 123.5M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -1.44 | -3.54 | .930 | -.400 | 1.20 | 1.29 |
| Q1 | -.370 | -.440 | -.380 | -.190 | .050 | — |
| Q2 | -.410 | -.460 | -.090 | -.160 | 2.07 | — |
| Q3 | -.320 | -.430 | -.200 | .030 | .255 | — |
| Q4 | -.344* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -2.20* |
| 1.55* |
| -.077* |
| .232 |
| — |
Debt level and coverage